VivoSeq
Infectious Disease

Invasive Fungal Infection

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Invasive Fungal Infection is an early-stage landscape with 0 programs across 2 companies. The most active players are Merck & Co., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Recruiting3 · 21%
Unknown status3 · 21%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
Recruiting·NNantes University Hospital·Phase 2·NCT06541067·30 enrolled
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT04665037·40 enrolled
Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection
Recruiting·BBiosergen AS·Phase 1/2·NCT06678113·15 enrolled
A Real-World Observational Study of the Effectiveness, Safety, and Therapeutic Drug Monitoring of Liposomal Amphotericin B in Solid Organ Transplant Recipients With Invasive Fungal Disease
Not yet recruiting·SSichuan Provincial People's Hospital·N/A·NCT07656493·120 enrolled
Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection
Completed·MMedical Research Council·Phase 3·NCT00003315·200 enrolled
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00811928·252 enrolled
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
Completed·—·Phase 4·NCT06413056·56 enrolled
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
Completed·SServices Institute of Medical Sciences, Pakistan·Phase 3·NCT05848492·110 enrolled
Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection
Completed·Pfizer logoPfizer·N/A·NCT01137292·177 enrolled
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00811642·63 enrolled
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Completed·RRadboud University Medical Center·N/A·NCT01533558·20 enrolled
Association of Plasma Transfusions and Invasive Fungal Infection
Unknown status·—·N/A·NCT03149562·500 enrolled
Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT02510053·40 enrolled
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT01501708·55 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)